Published : Sep 2019
Tables : 200
Figures : 120
Category : Healthcare
No. of Pages : 250
Report Code : HC-1275
Global Molecular Diagnostics Market is estimated to value over USD 12.6 billion by 2026 end and register a CAGR of over 8.9% during the forecast period 2019 to 2026. The reagents subjugated the global molecular diagnostics market with respect to revenue in 2018. Rising usage of reagents in testing molecular diagnostics, high demand for diagnostic tests provided over-the-counter and increasing adoption of such tests in nonmedical applications are some of the factors bolstering the global molecular diagnostics market growth. The central laboratories subjugated the market with respect to revenue share in 2018 due to high procedural volumes and a substantial prevalence of additional support with respect to infrastructure and manpower. The segment that is predicted to showcase rapid growth over the forecast period is the point of care segment. Rising demands for patient care at bedside due to prospering home healthcare along with rising penetration of localised establishments of healthcare is one of the primary factors responsible for its rapid growth. Furthermore, OTC products or self-tests are gaining popularity with consistent improvements in healthcare facilities and levels of patient awareness is anticipated to assist in the segment growth. The PCR segment subjugated the global molecular diagnostics market in 2018. PCR is a commonly used molecular diagnostics technology. Advancements and increased usage in PCR methods like multiplex PCR are some of the key factors responsible for the overall global molecular diagnostics market growth. Sequencing is predicted to showcase substantial growth during the forecast time frame due to factors like rising portability and likely cos reduction of DNA sequencers coupled with the NGS methods, offering high output sequencing and analysis of gene data. Moreover, In Situ Hybridization is expected to showcase significant growth over the forecast period. An increase in the population affected by cancer and the necessity for early diagnosis of cancer are some of the key factors aiding in the expansion of the overall global molecular diagnostics market size. Increasing prevalence of cancer and the development of novel tests like companion diagnostics for diagnosing cancer are some of the important factors that are predicted to contribute to the high value of CAGR during the forecast period. North America led the market in terms of generating revenue in 2018 and it is predicted to show the same molecular diagnostics market trend throughout the forecast period. North America is the leader of the industry due to the provisions of an established infrastructure for diagnostics, advancements in technology and rising awareness of patients. Massive prevalence of patient population and numerous unsatisfied clinical needs are expected to steer the market in the Asia Pacific region. Increasing economic initiatives by the governments of India and China in order to enhance the healthcare infrastructure are factors that are predicted to spur market augmentation. Key market players included in the global molecular diagnostics industry are Abbott, Becton, Dickinson and Co., Biomerieux SA, Bio-Rad Laboratories Inc., Dako, Danaher Corp., Hologic Inc., Illumina Inc., Johnson & Johnson Services, Novartis, Qiagen, Rocne Diagnostics, Siemens Healthcare Private Ltd., Sysmex Corp. Global Molecular Diagnostics Market Segmentation: By Product Instruments Reagents Others By Test Location Point of Care Self-Test or OTC Central Laboratories By Technology PCR - Multiplex PCR - Others ISH INAAT Chips and Microarrays Mass Spectrometry Sequencing TMA Others By Application Oncology - Breast Cancer - Prostate Cancer - Colorectal Cancer - Cervical Cancer - Kidney Cancer - Liver Cancer - Blood Cancer - Lung Cancer - Others Pharmacogenomics Infectious Disease - MRSA - Clostridium Difficile - Vancomycin-Resistant Enterococci - Carbapenem-Resistant Bacteria - Respiratory Syncytial Virus (RSV) - Candida - Tuberculosis and Drug-Resistant TBA - Meningitis - Gastrointestinal Panel Testing - Chlamydia - Gonorrhoea - HIV - Hepatitis C - Hepatitis B - Other Genetic Testing - New born Screening - Predictive and Presymptomatic Testing - Others Neurological Disease Cardiovascular Disease Microbiology Others By Region North America Europe Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global molecular diagnostics market by product, by test location, by technology, by application and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Global Molecular Diagnostics Market is estimated to value over USD 12.6 billion by 2026 end and register a CAGR of over 8.9% during the forecast period 2019 to 2026.
The reagents subjugated the global molecular diagnostics market with respect to revenue in 2018. Rising usage of reagents in testing molecular diagnostics, high demand for diagnostic tests provided over-the-counter and increasing adoption of such tests in nonmedical applications are some of the factors bolstering the global molecular diagnostics market growth.
The central laboratories subjugated the market with respect to revenue share in 2018 due to high procedural volumes and a substantial prevalence of additional support with respect to infrastructure and manpower.
The segment that is predicted to showcase rapid growth over the forecast period is the point of care segment. Rising demands for patient care at bedside due to prospering home healthcare along with rising penetration of localised establishments of healthcare is one of the primary factors responsible for its rapid growth. Furthermore, OTC products or self-tests are gaining popularity with consistent improvements in healthcare facilities and levels of patient awareness is anticipated to assist in the segment growth.
The PCR segment subjugated the global molecular diagnostics market in 2018. PCR is a commonly used molecular diagnostics technology. Advancements and increased usage in PCR methods like multiplex PCR are some of the key factors responsible for the overall global molecular diagnostics market growth.
Sequencing is predicted to showcase substantial growth during the forecast time frame due to factors like rising portability and likely cos reduction of DNA sequencers coupled with the NGS methods, offering high output sequencing and analysis of gene data.
Moreover, In Situ Hybridization is expected to showcase significant growth over the forecast period. An increase in the population affected by cancer and the necessity for early diagnosis of cancer are some of the key factors aiding in the expansion of the overall global molecular diagnostics market size.
Increasing prevalence of cancer and the development of novel tests like companion diagnostics for diagnosing cancer are some of the important factors that are predicted to contribute to the high value of CAGR during the forecast period.
North America led the market in terms of generating revenue in 2018 and it is predicted to show the same molecular diagnostics market trend throughout the forecast period. North America is the leader of the industry due to the provisions of an established infrastructure for diagnostics, advancements in technology and rising awareness of patients.
Massive prevalence of patient population and numerous unsatisfied clinical needs are expected to steer the market in the Asia Pacific region. Increasing economic initiatives by the governments of India and China in order to enhance the healthcare infrastructure are factors that are predicted to spur market augmentation.
Key market players included in the global molecular diagnostics industry are Abbott, Becton, Dickinson and Co., Biomerieux SA, Bio-Rad Laboratories Inc., Dako, Danaher Corp., Hologic Inc., Illumina Inc., Johnson & Johnson Services, Novartis, Qiagen, Rocne Diagnostics, Siemens Healthcare Private Ltd., Sysmex Corp.
Global Molecular Diagnostics Market Segmentation:
By Product
By Test Location
By Technology
- Multiplex PCR
- Others
By Application
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Kidney Cancer
- Liver Cancer
- Blood Cancer
- Lung Cancer
- MRSA
- Clostridium Difficile
- Vancomycin-Resistant Enterococci
- Carbapenem-Resistant Bacteria
- Respiratory Syncytial Virus (RSV)
- Candida
- Tuberculosis and Drug-Resistant TBA
- Meningitis
- Gastrointestinal Panel Testing
- Chlamydia
- Gonorrhoea
- HIV
- Hepatitis C
- Hepatitis B
- Other
- New born Screening
- Predictive and Presymptomatic Testing
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Chapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definition 1.3. Information Procurement 1.3.1. Purchased database 1.3.2. FutureWise’s internal database 1.3.3. Secondary sources & Third party perspectives 1.3.4. Primary research 1.4. Information Analysis 1.4.1. Data analysis models 1.5. Market Formulation & Data Visualization 1.6. Data Validation & Publishing Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Molecular Diagnostics Market Variables, Trends & Scope 3.1. Molecular Diagnostics Market Lineage outlook 3.1.1. IVD market outlook 3.2. Penetration & Growth Prospect Mapping 3.3. Regulatory Framework 3.3.1. Reimbursement framework 3.3.2. Standards & compliances 3.4. Market Dynamics 3.4.1. Market driver analysis 3.4.1.1. Increase in geriatric population 3.4.1.2. Introduction of technologically advanced products 3.4.1.3. Increase in demand for point-of-care facilities 3.4.1.4. Growing prevalence of target diseases 3.4.1.5. Increasing external funding for R&D 3.4.2. Market restraint analysis 3.4.2.1. Presence of ambiguous regulatory framework 3.4.2.2 High prices of molecular diagnostics tests 3.5. Molecular Diagnostics Market Analysis Tools 3.5.1. Industry analysis - Porter’s 3.5.1.1. Supplier power (Moderate due to requirement of high-quality raw materials) 3.5.1.2. Buyer power (Low due to limited number of established providers) 3.5.1.3. Substitution threat (Moderate due to high prices of molecular tests) 3.5.1.4. New entrants’ threat (Moderate due to manufacturing capital is high) 3.5.1.5. Competitive rivalry (High due to presence of many key players) 3.5.2. PESTEL analysis 3.5.2.1. Political landscape 3.5.2.2. Environmental landscape 3.5.2.3. Social landscape 3.5.2.4. Technology landscape 3.5.2.5. Legal landscape 3.5.3. Major deals & strategic alliances analysis 3.5.3.1. Joint ventures 3.5.3.2. Mergers & acquisitions 3.5.3.3. Licensing & partnership 3.5.3.4. Technology collaborations 3.5.3.5. Strategic divestments Chapter 4. Molecular Diagnostics Market - Competitive Analysis 4.1. Recent Developments & Impact Analysis, by Key Market Participants 4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players) 4.3. Vendor Landscape 4.3.1. List of key distributors and channel partners 4.3.2. Key company market share analysis, 2018 4.4. Public Companies 4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances) 4.4.2. Company market share 4.4.3. Competitive dashboard analysis 4.4.4. Market differentiators 4.4.5. Synergy analysis: Major deals & strategic alliances 4.5. Private Companies 4.5.1. List of key emerging companies 4.5.2. Regional network map 4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience) Chapter 5. Molecular Diagnostics Market: Product Estimates & Trend Analysis 5.1. Definitions & Scope 5.2. Product Market Share Analysis, 2018 & 2026 5.3. Molecular Diagnostics Market, by Product, 2014 to 2026 5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following, 5.4.1. Instruments 5.4.1.1 Instrument market, 2014 - 2026 (USD Million) 5.4.2. Reagents 5.4.2.1 Reagents market, 2014 - 2026 (USD Million) 5.4.3. Others 5.4.3.1 Others market, 2014 - 2026 (USD Million) Chapter 6. Molecular Diagnostics Market: Test Location Estimates & Trend Analysis 6.1. Definitions & Scope 6.2. Test Location Market Share Analysis, 2018 & 2026 6.3. Molecular Diagnostics Market, by Test Location, 2014 to 2026 6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following, 6.4.1. Point of care 6.4.1.1 Point of care market, 2014 - 2026 (USD Million) 6.4.2. Self-test or OTC 6.4.2.1 Self-test or OTC market, 2014 - 2026 (USD Million) 6.4.3. Central laboratories 6.4.3.1 Central laboratories market, 2014 - 2026 (USD Million) Chapter 7. Molecular Diagnostics Market: Technology Estimates & Trend Analysis 7.1. Definitions & Scope 7.2. Technology Market Share Analysis, 2018 & 2026 7.3. Molecular Diagnostics Market, by Technology, 2014 to 2026 7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following, 7.4.1. PCR 7.4.1.1 PCR market, 2014 - 2026 (USD Million) 7.4.1.2 Multiplex PCR 7.4.1.2.1 Multiplex PCR market, 2014 - 2026 (USD Million) 7.4.1.3 Others 7.4.1.3.1 Others market, 2014 - 2026 (USD Million) 7.4.2. ISH 7.4.2.1 ISH market, 2014 - 2026 (USD Million) 7.4.3. INAAT 7.4.3.1 INAAT market, 2014 - 2026 (USD Million) 7.4.4. Chips and microarrays 7.4.4.1 Chips and microarrays market, 2014 - 2026 (USD Million) 7.4.5. Mass spectrometry 7.4.5.1 Mass spectrometry market, 2014 - 2026 (USD Million) 7.4.6. Sequencing 7.4.6.1 Sequencing market, 2014 - 2026 (USD Million) 7.4.7. TMA 7.4.7.1 TMA market, 2014 - 2026 (USD Million) 7.4.8. Others 7.4.8.1 Others market, 2014 - 2026 (USD Million) 7.5. Technology Markets, by Product, 2014 to 2026: 7.5.1. PCR 7.5.1.1 Instruments 7.5.1.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.1.2 Reagents 7.5.1.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.1.3 Others 7.5.1.3.1 Others market, 2014 - 2026 (USD Million) 7.5.2. ISH 7.5.2.1 Instruments 7.5.2.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.2.2. Reagents 7.5.2.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.2.3 Others 7.5.2.3.1 Others market, 2014 - 2026 (USD Million) 7.5.3. INAAT 7.5.3.1 Instruments 7.5.3.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.3.2. Reagents 7.5.3.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.3.3 Others 7.5.3.3.1 Others market, 2014 - 2026 (USD Million) 7.5.4. Chips and microarrays 7.5.4.1 Instruments 7.5.4.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.4.2. Reagents 7.5.4.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.4.3 Others 7.5.4.3.1 Others market, 2014 - 2026 (USD Million) 7.5.5. Mass spectrometry 7.5.5.1 Instruments 7.5.5.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.5.2. Reagents 7.5.5.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.5.3 Others 7.5.5.3.1 Others market, 2014 - 2026 (USD Million) 7.5.6. Sequencing 7.5.6.1 Instruments 7.5.6.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.6.2. Reagents 7.5.6.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.6.3 Others 7.5.6.3.1 Others market, 2014 - 2026 (USD Million) 7.5.7. TMA 7.5.7.1 Instruments 7.5.7.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.7.2. Reagents 7.5.7.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.7.3 Others 7.5.7.3.1 Others market, 2014 - 2026 (USD Million) 7.5.8. Others 7.5.8.1 Instruments 7.5.8.1.1 Instrument market, 2014 - 2026 (USD Million) 7.5.8.2. Reagents 7.5.8.2.1 Reagents market, 2014 - 2026 (USD Million) 7.5.8.3 Others 7.5.8.3.1 Others market, 2014 - 2026 (USD Million) Chapter 8. Molecular Diagnostics Market: Application Estimates & Trend Analysis 8.1. Definitions & Scope 8.2. Application Market Share Analysis, 2018 & 2026 8.3. Molecular Diagnostics Market, by Application, 2014 to 2026 8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following, 8.4.1. Oncology 8.4.1.1 Oncology market, 2014 - 2026 (USD Million) 8.4.1.2 Breast cancer 8.4.1.2.1 Breast cancer market, 2014 - 2026 (USD Million) 8.4.1.3 Prostate cancer 8.4.1.3.1 Prostate cancer market, 2014 - 2026 (USD Million) 8.4.1.4 Colorectal cancer 8.4.1.4.1 Colorectal cancer market, 2014 - 2026 (USD Million) 8.4.1.5 Cervical cancer 8.4.1.5.1 Cervical cancer market, 2014 - 2026 (USD Million) 8.4.1.6 Kidney cancer 8.4.1.6.1 Kidney cancer market, 2014 - 2026 (USD Million) 8.4.1.7 Liver cancer 8.4.1.7.1 Liver cancer market, 2014 - 2026 (USD Million) 8.4.1.8 Blood cancer 8.4.1.8.1 Blood cancer market, 2014 - 2026 (USD Million) 8.4.1.9 Lung cancer 8.4.1.9.1 Lung cancer market, 2014 - 2026 (USD Million) 8.4.1.10 Others 8.4.1.10.1 Others market, 2014 - 2026 (USD Million) 8.4.2. Pharmacogenomics 8.4.2.1 Pharmacogenomics market, 2014 - 2026 (USD Million) 8.4.3. Infectious disease 8.4.3.1 Infectious disease market, 2014 - 2026 (USD Million) 8.4.3.2 MRSA 8.4.3.2.1 MRSA market, 2014 - 2026 (USD Million) 8.4.3.3 Clostridium difficile 8.4.3.3.1 Clostridium difficile market, 2014 - 2026 (USD Million) 8.4.3.4 Vancomycin-resistant enterococci 8.4.3.4.1 Vancomycin-resistant enterococci market, 2014 - 2026 (USD Million) 8.4.3.5 Carbapenem-resistant bacteria 8.4.3.5.1 Carbapenem-resistant bacteria, 2014 - 2026 (USD Million) 8.4.3.6 Flu 8.4.3.6.1 Flu market, 2014 - 2026 (USD Million) 8.4.3.7 Respiratory syncytial virus (RSV) 8.4.3.7.1 Respiratory syncytial virus (RSV) market, 2014 - 2026 (USD Million) 8.4.3.8 Candida 8.4.3.8.1 Candida market, 2014 - 2026 (USD Million) 8.4.3.9 Tuberculosis and drug-resistant TBA 8.4.3.9.1 Tuberculosis and drug-resistant TBA market, 2014 - 2026 (USD Million) 8.4.3.10 Meningitis 8.4.3.10.1 Meningitis market, 2014 - 2026 (USD Million) 8.4.3.11 Gastrointestinal panel testing 8.4.3.11.1 Gastrointestinal panel testing market, 2014 - 2026 (USD Million) 8.4.3.12 Chlamydia 8.4.3.12.1 Chlamydia market, 2014 - 2026 (USD Million) 8.4.3.13 Gonorrhea 8.4.3.13.1 Gonorrhea market, 2014 - 2026 (USD Million) 8.4.3.14 HIV 8.4.3.14.1 HIV market, 2014 - 2026 (USD Million) 8.4.3.15 Hepatitis C 8.4.3.15.1 Hepatitis C market, 2014 - 2026 (USD Million) 8.4.3.16 Hepatitis B 8.4.3.16.1 Hepatitis B market, 2014 - 2026 (USD Million) 8.4.3.17 Other 8.4.3.17.1 Other market, 2014 - 2026 (USD Million) 8.4.4. Genetic testing 8.4.4.1 Genetic testing market, 2014 - 2026 (USD Million) 8.4.4.2 Newborn screening 8.4.4.2.1 Newborn screening market, 2014 - 2026 (USD Million) 8.4.4.3 Predictive and presymptomatic testing 8.4.4.3.1 Predictive and presymptomatic testing market, 2014 - 2026 (USD Million) 8.4.4.4 Others 8.4.4.4.1 Others market, 2014 - 2026 (USD Million) 8.4.5. Neurological disease 8.4.5.1 Neurological disease market, 2014 - 2026 (USD Million) 8.4.6. Cardiovascular disease 8.4.6.1 Cardiovascular disease market, 2014 - 2026 (USD Million) 8.4.7. Microbiology 8.4.7.1 Microbiology market, 2014 - 2026 (USD Million) 8.4.8. Others 8.4.8.1 Others market, 2014 - 2026 (USD Million) Chapter 9 Molecular Diagnostics Market: Regional Estimates & Trend Analysis, by Product, Test Location, Technology, & Application 9.1 Molecular Diagnostics Market: Regional Movement Analysis, 2018 & 2026 9.2 Molecular Diagnostics Market: Leading Players, 2018: 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological) 9.3.1. North America 9.3.2. Europe 9.3.3. Asia Pacific 9.3.4. Latin America 9.3.5. Middle East & Africa 9.4 North America 9.4.1 North America market, 2014 - 2026 (USD Million) 9.4.2 U.S. 9.4.2.1 U.S. market, 2014 - 2026 (USD Million) 9.4.3 Canada 9.4.3.1 Canada market, 2014 - 2026 (USD Million) 9.5. Europe 9.5.1 Europe market, 2014 - 2026 (USD Million) 9.5.2 U.K. 9.5.2.1 U.K. market, 2014 - 2026 (USD Million) 9.5.3 Germany 9.5.3.1 Germany market, 2014 - 2026 (USD Million) 9.5.4 France 9.5.4.1 France market, 2014 - 2026 (USD Million) 9.5.5 Spain 9.5.5.1 Spain market, 2014 - 2026 (USD Million) 9.5.6 Italy 9.5.6.1 Italy market, 2014 - 2026 (USD Million) 9.5.7 Belgium 9.5.7.1 Belgium market, 2014 - 2026 (USD Million) 9.5.8 Switzerland 9.5.8.1 Switzerland market, 2014 - 2026 (USD Million) 9.5.9 Netherlands 9.5.9.1 Netherlands market, 2014 - 2026 (USD Million) 9.5.10 Poland 9.5.10.1 Poland market, 2014 - 2026 (USD Million) 9.5.11 Austria 9.5.11.1 Austria market, 2014 - 2026 (USD Million) 9.5.12 Greece 9.5.12.1 Greece market, 2014 - 2026 (USD Million) 9.5.13 Sweden 9.5.13.1 Sweden market, 2014 - 2026 (USD Million) 9.5.14 Turkey 9.5.14.1 Turkey market, 2014 - 2026 (USD Million) 9.5.15 Finland 9.5.15.1 Finland market, 2014 - 2026 (USD Million) 9.6 Asia Pacific 9.6.1 Asia Pacific market, 2014 - 2026 (USD Million) 9.6.2 Japan 9.6.2.1 Japan market, 2014 - 2026 (USD Million) 9.6.3 China 9.6.3.1 China market, 2014 - 2026 (USD Million) 9.6.4 India 9.6.4.1 India market, 2014 - 2026 (USD Million) 9.6.5 Australia 9.6.5.1 Australia market, 2014 - 2026 (USD Million) 9.6.6 New Zealand 9.6.6.1 New Zealand market, 2014 - 2026 (USD Million) 9.6.7 Sri Lanka 9.6.7.1 Sri Lanka market, 2014 - 2026 (USD Million) 9.6.8 Malaysia 9.6.8.1 Malaysia market, 2014 - 2026 (USD Million) 9.6.9 Thailand 9.6.9.1 Thailand market, 2014 - 2026 (USD Million) 9.6.10 Vietnam 9.6.10.1 Vietnam market, 2014 - 2026 (USD Million) 9.6.11 Singapore 9.6.11.1 Singapore market, 2014 - 2026 (USD Million) 9.7 Latin America 9.7.1 Latin America market, 2014 - 2026 (USD Million) 9.7.2 Brazil 9.7.2.1 Brazil market, 2014 - 2026 (USD Million) 9.7.3 Mexico 9.7.3.1 Mexico market, 2014 - 2026 (USD Million) 9.7.4 Colombia 9.7.4.1 Colombia market, 2014 - 2026 (USD Million) 9.7.5 Chile 9.7.5.1 Chile market, 2014 - 2026 (USD Million) 9.7.6 Peru 9.7.6.1 Peru market, 2014 - 2026 (USD Million) 9.7.7 Argentina 9.7.7.1 Argentina market, 2014 - 2026 (USD Million) 9.8 MEA 9.8.1 MEA market, 2014 - 2026 (USD Million) 9.8.2 South Africa 9.8.2.1 South Africa market, 2014 - 2026 (USD Million) 9.8.3 Saudi Arabia 9.8.3.1 Saudi Arabia market, 2014 - 2026 (USD Million) 9.8.4 Jordan 9.8.4.1 Jordan Arabia market, 2014 - 2026 (USD Million) 9.8.5 UAE 9.8.5.1 UAE Arabia market, 2014 - 2026 (USD Million) 9.8.6 Qatar 9.8.6.1 Qatar Arabia market, 2014 - 2026 (USD Million) 9.8.7 Nigeria 9.8.7.1 Nigeria Arabia market, 2014 - 2026 (USD Million) 9.8.8 Egypt 9.8.8.1 Egypt Arabia market, 2014 - 2026 (USD Million) Chapter 10 Competitive Landscape 10.1 Strategy Framework 10.2 Heat Map Analysis of Private Companies 10.2.1 Company size 10.2.2 Distribution network 10.2.3 Product portfolio 10.2.4 Segment coverage 10.2.5 Geographic presence 10.2.6 Collaborations 10.2.7 Conclusion 10.3 Abbott 10.3.1 Company overview 10.3.2 Financial performance 10.3.3 Product benchmarking 10.3.4 Strategic initiatives 10.4 Becton, Dickinson and Company 10.4.1 Company overview 10.4.2 Financial performance 10.4.3 Product benchmarking 10.4.4 Strategic initiatives 10.5 bioMérieux SA 10.5.1 Company overview 10.5.2 Financial performance 10.5.3 Product benchmarking 10.5.4 Strategic initiatives 10.6 Bio-Rad Laboratories, Inc. 10.6.1 Company overview 10.6.2 Financial performance 10.6.3 Product benchmarking 10.6.4 Strategic initiatives 10.7 Dako 10.7.1 Company overview 10.7.2 Financial performance 10.7.3 Product benchmarking 10.7.4 Strategic initiatives 10.8 Danaher Corporation 10.8.1 Company overview 10.8.2 Financial performance 10.8.3 Product benchmarking 10.8.4 Strategic initiatives 10.9 Hologic, Inc. (Gen Probe) 10.9.1 Company overview 10.9.2 Financial performance 10.9.3 Product benchmarking 10.9.4 Strategic initiatives 10.10 Illumina, Inc. 10.10.1 Company overview 10.10.2 Product benchmarking 10.10.3 Strategic initiatives 10.11 Johnson & Johnson Services, Inc 10.11.1 Company Overview 10.11.2 Financial performance 10.11.3 Product benchmarking 10.11.4 Strategic initiatives 10.12 Novartis (Grifols) 10.12.1 Company overview 10.12.2 Financial performance 10.12.3 Product benchmarking 10.12.4 Strategic initiatives 10.13 Qiagen 10.13.1 Company overview 10.13.2 Financial overview 10.13.3 Product benchmarking 10.13.4 Strategic initiatives 10.14 Roche Diagnostics 10.14.1 Company overview 10.14.2 Financial overview 10.14.3 Product benchmarking 10.14.4 Strategic initiatives 10.15 Siemens Healthcare Private Limited 10.15.1 Company overview 10.15.2 Financial performance 10.15.3 Product benchmarking 10.15.4 Strategic initiatives 10.16 Sysmex Corporation 10.16.1 Company overview 10.16.2 Financial performance 10.16.3 Products benchmarking 10.16.4 Strategic initiatives Chapter 11 Research Finding and Conclusion Chapter 12 Research Methodology Chapter 13 Research Data Source
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. FutureWise’s internal database
1.3.3. Secondary sources & Third party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Molecular Diagnostics Market Variables, Trends & Scope
3.1. Molecular Diagnostics Market Lineage outlook
3.1.1. IVD market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Regulatory Framework
3.3.1. Reimbursement framework
3.3.2. Standards & compliances
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increase in geriatric population
3.4.1.2. Introduction of technologically advanced products
3.4.1.3. Increase in demand for point-of-care facilities
3.4.1.4. Growing prevalence of target diseases
3.4.1.5. Increasing external funding for R&D
3.4.2. Market restraint analysis
3.4.2.1. Presence of ambiguous regulatory framework
3.4.2.2 High prices of molecular diagnostics tests
3.5. Molecular Diagnostics Market Analysis Tools
3.5.1. Industry analysis - Porter’s
3.5.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
3.5.1.2. Buyer power (Low due to limited number of established providers)
3.5.1.3. Substitution threat (Moderate due to high prices of molecular tests)
3.5.1.4. New entrants’ threat (Moderate due to manufacturing capital is high)
3.5.1.5. Competitive rivalry (High due to presence of many key players)
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Environmental landscape
3.5.2.3. Social landscape
3.5.2.4. Technology landscape
3.5.2.5. Legal landscape
3.5.3. Major deals & strategic alliances analysis
3.5.3.1. Joint ventures
3.5.3.2. Mergers & acquisitions
3.5.3.3. Licensing & partnership
3.5.3.4. Technology collaborations
3.5.3.5. Strategic divestments
Chapter 4. Molecular Diagnostics Market - Competitive Analysis
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key company market share analysis, 2018
4.4. Public Companies
4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.4.2. Company market share
4.4.3. Competitive dashboard analysis
4.4.4. Market differentiators
4.4.5. Synergy analysis: Major deals & strategic alliances
4.5. Private Companies
4.5.1. List of key emerging companies
4.5.2. Regional network map
4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Molecular Diagnostics Market: Product Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Product Market Share Analysis, 2018 & 2026
5.3. Molecular Diagnostics Market, by Product, 2014 to 2026
5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.4.1. Instruments
5.4.1.1 Instrument market, 2014 - 2026 (USD Million)
5.4.2. Reagents
5.4.2.1 Reagents market, 2014 - 2026 (USD Million)
5.4.3. Others
5.4.3.1 Others market, 2014 - 2026 (USD Million)
Chapter 6. Molecular Diagnostics Market: Test Location Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Test Location Market Share Analysis, 2018 & 2026
6.3. Molecular Diagnostics Market, by Test Location, 2014 to 2026
6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
6.4.1. Point of care
6.4.1.1 Point of care market, 2014 - 2026 (USD Million)
6.4.2. Self-test or OTC
6.4.2.1 Self-test or OTC market, 2014 - 2026 (USD Million)
6.4.3. Central laboratories
6.4.3.1 Central laboratories market, 2014 - 2026 (USD Million)
Chapter 7. Molecular Diagnostics Market: Technology Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Technology Market Share Analysis, 2018 & 2026
7.3. Molecular Diagnostics Market, by Technology, 2014 to 2026
7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
7.4.1. PCR
7.4.1.1 PCR market, 2014 - 2026 (USD Million)
7.4.1.2 Multiplex PCR
7.4.1.2.1 Multiplex PCR market, 2014 - 2026 (USD Million)
7.4.1.3 Others
7.4.1.3.1 Others market, 2014 - 2026 (USD Million)
7.4.2. ISH
7.4.2.1 ISH market, 2014 - 2026 (USD Million)
7.4.3. INAAT
7.4.3.1 INAAT market, 2014 - 2026 (USD Million)
7.4.4. Chips and microarrays
7.4.4.1 Chips and microarrays market, 2014 - 2026 (USD Million)
7.4.5. Mass spectrometry
7.4.5.1 Mass spectrometry market, 2014 - 2026 (USD Million)
7.4.6. Sequencing
7.4.6.1 Sequencing market, 2014 - 2026 (USD Million)
7.4.7. TMA
7.4.7.1 TMA market, 2014 - 2026 (USD Million)
7.4.8. Others
7.4.8.1 Others market, 2014 - 2026 (USD Million)
7.5. Technology Markets, by Product, 2014 to 2026:
7.5.1. PCR
7.5.1.1 Instruments
7.5.1.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.1.2 Reagents
7.5.1.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.1.3 Others
7.5.1.3.1 Others market, 2014 - 2026 (USD Million)
7.5.2. ISH
7.5.2.1 Instruments
7.5.2.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.2.2. Reagents
7.5.2.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.2.3 Others
7.5.2.3.1 Others market, 2014 - 2026 (USD Million)
7.5.3. INAAT
7.5.3.1 Instruments
7.5.3.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.3.2. Reagents
7.5.3.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.3.3 Others
7.5.3.3.1 Others market, 2014 - 2026 (USD Million)
7.5.4. Chips and microarrays
7.5.4.1 Instruments
7.5.4.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.4.2. Reagents
7.5.4.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.4.3 Others
7.5.4.3.1 Others market, 2014 - 2026 (USD Million)
7.5.5. Mass spectrometry
7.5.5.1 Instruments
7.5.5.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.5.2. Reagents
7.5.5.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.5.3 Others
7.5.5.3.1 Others market, 2014 - 2026 (USD Million)
7.5.6. Sequencing
7.5.6.1 Instruments
7.5.6.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.6.2. Reagents
7.5.6.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.6.3 Others
7.5.6.3.1 Others market, 2014 - 2026 (USD Million)
7.5.7. TMA
7.5.7.1 Instruments
7.5.7.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.7.2. Reagents
7.5.7.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.7.3 Others
7.5.7.3.1 Others market, 2014 - 2026 (USD Million)
7.5.8. Others
7.5.8.1 Instruments
7.5.8.1.1 Instrument market, 2014 - 2026 (USD Million)
7.5.8.2. Reagents
7.5.8.2.1 Reagents market, 2014 - 2026 (USD Million)
7.5.8.3 Others
7.5.8.3.1 Others market, 2014 - 2026 (USD Million)
Chapter 8. Molecular Diagnostics Market: Application Estimates & Trend Analysis
8.1. Definitions & Scope
8.2. Application Market Share Analysis, 2018 & 2026
8.3. Molecular Diagnostics Market, by Application, 2014 to 2026
8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
8.4.1. Oncology
8.4.1.1 Oncology market, 2014 - 2026 (USD Million)
8.4.1.2 Breast cancer
8.4.1.2.1 Breast cancer market, 2014 - 2026 (USD Million)
8.4.1.3 Prostate cancer
8.4.1.3.1 Prostate cancer market, 2014 - 2026 (USD Million)
8.4.1.4 Colorectal cancer
8.4.1.4.1 Colorectal cancer market, 2014 - 2026 (USD Million)
8.4.1.5 Cervical cancer
8.4.1.5.1 Cervical cancer market, 2014 - 2026 (USD Million)
8.4.1.6 Kidney cancer
8.4.1.6.1 Kidney cancer market, 2014 - 2026 (USD Million)
8.4.1.7 Liver cancer
8.4.1.7.1 Liver cancer market, 2014 - 2026 (USD Million)
8.4.1.8 Blood cancer
8.4.1.8.1 Blood cancer market, 2014 - 2026 (USD Million)
8.4.1.9 Lung cancer
8.4.1.9.1 Lung cancer market, 2014 - 2026 (USD Million)
8.4.1.10 Others
8.4.1.10.1 Others market, 2014 - 2026 (USD Million)
8.4.2. Pharmacogenomics
8.4.2.1 Pharmacogenomics market, 2014 - 2026 (USD Million)
8.4.3. Infectious disease
8.4.3.1 Infectious disease market, 2014 - 2026 (USD Million)
8.4.3.2 MRSA
8.4.3.2.1 MRSA market, 2014 - 2026 (USD Million)
8.4.3.3 Clostridium difficile
8.4.3.3.1 Clostridium difficile market, 2014 - 2026 (USD Million)
8.4.3.4 Vancomycin-resistant enterococci
8.4.3.4.1 Vancomycin-resistant enterococci market, 2014 - 2026 (USD Million)
8.4.3.5 Carbapenem-resistant bacteria
8.4.3.5.1 Carbapenem-resistant bacteria, 2014 - 2026 (USD Million)
8.4.3.6 Flu
8.4.3.6.1 Flu market, 2014 - 2026 (USD Million)
8.4.3.7 Respiratory syncytial virus (RSV)
8.4.3.7.1 Respiratory syncytial virus (RSV) market, 2014 - 2026 (USD Million)
8.4.3.8 Candida
8.4.3.8.1 Candida market, 2014 - 2026 (USD Million)
8.4.3.9 Tuberculosis and drug-resistant TBA
8.4.3.9.1 Tuberculosis and drug-resistant TBA market, 2014 - 2026 (USD Million)
8.4.3.10 Meningitis
8.4.3.10.1 Meningitis market, 2014 - 2026 (USD Million)
8.4.3.11 Gastrointestinal panel testing
8.4.3.11.1 Gastrointestinal panel testing market, 2014 - 2026 (USD Million)
8.4.3.12 Chlamydia
8.4.3.12.1 Chlamydia market, 2014 - 2026 (USD Million)
8.4.3.13 Gonorrhea
8.4.3.13.1 Gonorrhea market, 2014 - 2026 (USD Million)
8.4.3.14 HIV
8.4.3.14.1 HIV market, 2014 - 2026 (USD Million)
8.4.3.15 Hepatitis C
8.4.3.15.1 Hepatitis C market, 2014 - 2026 (USD Million)
8.4.3.16 Hepatitis B
8.4.3.16.1 Hepatitis B market, 2014 - 2026 (USD Million)
8.4.3.17 Other
8.4.3.17.1 Other market, 2014 - 2026 (USD Million)
8.4.4. Genetic testing
8.4.4.1 Genetic testing market, 2014 - 2026 (USD Million)
8.4.4.2 Newborn screening
8.4.4.2.1 Newborn screening market, 2014 - 2026 (USD Million)
8.4.4.3 Predictive and presymptomatic testing
8.4.4.3.1 Predictive and presymptomatic testing market, 2014 - 2026 (USD Million)
8.4.4.4 Others
8.4.4.4.1 Others market, 2014 - 2026 (USD Million)
8.4.5. Neurological disease
8.4.5.1 Neurological disease market, 2014 - 2026 (USD Million)
8.4.6. Cardiovascular disease
8.4.6.1 Cardiovascular disease market, 2014 - 2026 (USD Million)
8.4.7. Microbiology
8.4.7.1 Microbiology market, 2014 - 2026 (USD Million)
8.4.8. Others
8.4.8.1 Others market, 2014 - 2026 (USD Million)
Chapter 9 Molecular Diagnostics Market: Regional Estimates & Trend Analysis, by Product, Test Location, Technology, & Application
9.1 Molecular Diagnostics Market: Regional Movement Analysis, 2018 & 2026
9.2 Molecular Diagnostics Market: Leading Players, 2018:
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4 North America
9.4.1 North America market, 2014 - 2026 (USD Million)
9.4.2 U.S.
9.4.2.1 U.S. market, 2014 - 2026 (USD Million)
9.4.3 Canada
9.4.3.1 Canada market, 2014 - 2026 (USD Million)
9.5. Europe
9.5.1 Europe market, 2014 - 2026 (USD Million)
9.5.2 U.K.
9.5.2.1 U.K. market, 2014 - 2026 (USD Million)
9.5.3 Germany
9.5.3.1 Germany market, 2014 - 2026 (USD Million)
9.5.4 France
9.5.4.1 France market, 2014 - 2026 (USD Million)
9.5.5 Spain
9.5.5.1 Spain market, 2014 - 2026 (USD Million)
9.5.6 Italy
9.5.6.1 Italy market, 2014 - 2026 (USD Million)
9.5.7 Belgium
9.5.7.1 Belgium market, 2014 - 2026 (USD Million)
9.5.8 Switzerland
9.5.8.1 Switzerland market, 2014 - 2026 (USD Million)
9.5.9 Netherlands
9.5.9.1 Netherlands market, 2014 - 2026 (USD Million)
9.5.10 Poland
9.5.10.1 Poland market, 2014 - 2026 (USD Million)
9.5.11 Austria
9.5.11.1 Austria market, 2014 - 2026 (USD Million)
9.5.12 Greece
9.5.12.1 Greece market, 2014 - 2026 (USD Million)
9.5.13 Sweden
9.5.13.1 Sweden market, 2014 - 2026 (USD Million)
9.5.14 Turkey
9.5.14.1 Turkey market, 2014 - 2026 (USD Million)
9.5.15 Finland
9.5.15.1 Finland market, 2014 - 2026 (USD Million)
9.6 Asia Pacific
9.6.1 Asia Pacific market, 2014 - 2026 (USD Million)
9.6.2 Japan
9.6.2.1 Japan market, 2014 - 2026 (USD Million)
9.6.3 China
9.6.3.1 China market, 2014 - 2026 (USD Million)
9.6.4 India
9.6.4.1 India market, 2014 - 2026 (USD Million)
9.6.5 Australia
9.6.5.1 Australia market, 2014 - 2026 (USD Million)
9.6.6 New Zealand
9.6.6.1 New Zealand market, 2014 - 2026 (USD Million)
9.6.7 Sri Lanka
9.6.7.1 Sri Lanka market, 2014 - 2026 (USD Million)
9.6.8 Malaysia
9.6.8.1 Malaysia market, 2014 - 2026 (USD Million)
9.6.9 Thailand
9.6.9.1 Thailand market, 2014 - 2026 (USD Million)
9.6.10 Vietnam
9.6.10.1 Vietnam market, 2014 - 2026 (USD Million)
9.6.11 Singapore
9.6.11.1 Singapore market, 2014 - 2026 (USD Million)
9.7 Latin America
9.7.1 Latin America market, 2014 - 2026 (USD Million)
9.7.2 Brazil
9.7.2.1 Brazil market, 2014 - 2026 (USD Million)
9.7.3 Mexico
9.7.3.1 Mexico market, 2014 - 2026 (USD Million)
9.7.4 Colombia
9.7.4.1 Colombia market, 2014 - 2026 (USD Million)
9.7.5 Chile
9.7.5.1 Chile market, 2014 - 2026 (USD Million)
9.7.6 Peru
9.7.6.1 Peru market, 2014 - 2026 (USD Million)
9.7.7 Argentina
9.7.7.1 Argentina market, 2014 - 2026 (USD Million)
9.8 MEA
9.8.1 MEA market, 2014 - 2026 (USD Million)
9.8.2 South Africa
9.8.2.1 South Africa market, 2014 - 2026 (USD Million)
9.8.3 Saudi Arabia
9.8.3.1 Saudi Arabia market, 2014 - 2026 (USD Million)
9.8.4 Jordan
9.8.4.1 Jordan Arabia market, 2014 - 2026 (USD Million)
9.8.5 UAE
9.8.5.1 UAE Arabia market, 2014 - 2026 (USD Million)
9.8.6 Qatar
9.8.6.1 Qatar Arabia market, 2014 - 2026 (USD Million)
9.8.7 Nigeria
9.8.7.1 Nigeria Arabia market, 2014 - 2026 (USD Million)
9.8.8 Egypt
9.8.8.1 Egypt Arabia market, 2014 - 2026 (USD Million)
Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Heat Map Analysis of Private Companies
10.2.1 Company size
10.2.2 Distribution network
10.2.3 Product portfolio
10.2.4 Segment coverage
10.2.5 Geographic presence
10.2.6 Collaborations
10.2.7 Conclusion
10.3 Abbott
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Becton, Dickinson and Company
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 bioMérieux SA
10.5.1 Company overview
10.5.2 Financial performance
10.5.3 Product benchmarking
10.5.4 Strategic initiatives
10.6 Bio-Rad Laboratories, Inc.
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 Dako
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Product benchmarking
10.7.4 Strategic initiatives
10.8 Danaher Corporation
10.8.1 Company overview
10.8.2 Financial performance
10.8.3 Product benchmarking
10.8.4 Strategic initiatives
10.9 Hologic, Inc. (Gen Probe)
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Product benchmarking
10.9.4 Strategic initiatives
10.10 Illumina, Inc.
10.10.1 Company overview
10.10.2 Product benchmarking
10.10.3 Strategic initiatives
10.11 Johnson & Johnson Services, Inc
10.11.1 Company Overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 Novartis (Grifols)
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Product benchmarking
10.12.4 Strategic initiatives
10.13 Qiagen
10.13.1 Company overview
10.13.2 Financial overview
10.13.3 Product benchmarking
10.13.4 Strategic initiatives
10.14 Roche Diagnostics
10.14.1 Company overview
10.14.2 Financial overview
10.14.3 Product benchmarking
10.14.4 Strategic initiatives
10.15 Siemens Healthcare Private Limited
10.15.1 Company overview
10.15.2 Financial performance
10.15.3 Product benchmarking
10.15.4 Strategic initiatives
10.16 Sysmex Corporation
10.16.1 Company overview
10.16.2 Financial performance
10.16.3 Products benchmarking
10.16.4 Strategic initiatives
Chapter 11 Research Finding and Conclusion
Chapter 12 Research Methodology
Chapter 13 Research Data Source
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics